Get the Stockscreener App
5.60
1.23%
-0.07
After Hours:
5.58
-0.02
-0.36%
Mannkind Corp stock is traded at $5.60, with a volume of 2.73M.
It is down -1.23% in the last 24 hours and up +0.18% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$5.67
Open:
$5.73
24h Volume:
2.73M
Relative Volume:
0.72
Market Cap:
$1.72B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
112.00
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-3.28%
1M Performance:
+0.18%
6M Performance:
+54.70%
1Y Performance:
-15.15%
1-Day Range:
$5.575
$5.73
1-Week Range:
$5.555
$5.82
52-Week Range:
$3.3812
$6.67
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.60 | 1.74B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
MannKind Shares FUROSCIX® Business Updates - Yahoo Finance
Can MannKind Corporation stock hit record highs again2025 Valuation Update & Consistent Growth Stock Picks - ulpravda.ru
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Insider Sell: Michael Castagna Sells 65,804 Shares of MannKind C - GuruFocus
Is MannKind Corporation stock affected by interest rate hikesMarket Movement Recap & Reliable Intraday Trade Alerts - DonanımHaber
How MannKind Corporation stock performs in weak economyMarket Growth Report & Weekly Top Gainers Alerts - Улправда
Insider Sell: Michael Castagna Sells 42,116 Shares of MannKind C - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MannKind (NASDAQ: MNKD) adds audited and pro forma scPharma results to merger filing - Stock Titan
MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA - simplywall.st
Short Squeeze: Will SHPH stock gain from lower inflation2025 Market WrapUp & Free Weekly Watchlist of Top Performers - moha.gov.vn
The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector - simplywall.st
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
MNKD FinancialsIncome Statement - Quiver Quantitative
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView — Track All Markets
VP Thomson Sells 147,780 ($823.1K) Of MannKind Corp [MNKD] - TradingView
Is MannKind Corporation (NNFN) stock undervalued after correctionWeekly Investment Report & Growth Focused Stock Reports - Newser
How MannKind Corporation (NNFN) stock moves in volatile trading sessionsJuly 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients (NASDAQ:MNKD) - Seeking Alpha
Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback? - Yahoo Finance
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation (NNFN) stock attract analyst upgradesQuarterly Profit Report & AI Based Buy and Sell Signals - Newser
Can MannKind Corporation (NNFN) stock sustain double digit ROEMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
FDA Reviewing 10-Second Treatment for Edema in Heart Failure - Diagnostic and Interventional Cardiology
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector - Investing.com
MannKind (MNKD) Awaits FDA Decision on FUROSCIX ReadyFlow Autoin - GuruFocus
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - The Manila Times
MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):